Verrica Pharmaceuticals
VRCA
27 hedge funds and large institutions have $164M invested in Verrica Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 27 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
3.2% more ownership
Funds ownership: 0% → 3.2% (+3.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$66.8M |
| 2 |
O
OrbiMed
New York
|
+$29M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.5M |
| 4 |
FI
Fosun International
Hong Kong,
China
|
+$15.6M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
+$8.18M |
Top Sellers
VRCA Hedge Fund Activity: Q2 2018 in Review
27 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q2 2018, worth a combined $164M.
Buyers outnumbered sellers: 27 funds opened new VRCA positions and 0 closed out — a net gain of 27 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $66.8M.
- 27 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q2 2018, up from 0 in Q1 2018.
- Funds reported $164M of Verrica Pharmaceuticals stock for Q2 2018.
- 27 funds opened new Verrica Pharmaceuticals positions in Q2 2018 and 0 closed out, a net change of +27 holders.
- The largest Verrica Pharmaceuticals buyer in Q2 2018 was Perceptive Advisors, an estimated $66.8M added.
Based on aggregated 13F filings for Q2 2018.